astellas_tokyo_copy

Astellas snatches up oncology firm Ganymed for $1.4 billion

pharmafile | October 31, 2016 | News story | Research and Development, Sales and Marketing |ย ย Astellas, Ganymed, IMAB362ย 

Japanese pharma firm Astellas is set to bolster its oncology business with the acquisition of Ganymed Pharmaceuticals in a deal worth up to $1.4 billion.

Ganymed, based in Germany, focuses on treatment of cancer using ideal monoclonal antibodies (IMABs) which target proteins present in cancer cells but do not bind to healthy cells. It will become a wholly owned subsidiary of Astellas for an initial payment of $461 million, followed by milestone payments of up to $940 million based on the progress of Ganymedโ€™s IMAB362. IMAB362 is gastroesophageal cancer candidate designed to target the tight junction protein Claudin-18.2 (CLDN18.2), and has proved itself this year in mid-stage trials to be capable of significantly improving progression-free survival as a combination treatment for gastric cancer as opposed to chemotherapy alone.

Commenting on the venture, Astellas CEO Yoshihiko Hatanaka remarked: “Oncology is one of our focus therapeutic areas and key drivers for our growth.

Advertisement

โ€œWe aim to deliver a potential new therapeutic option to cancer patients who currently have limited treatment options available to them. The acquisition of Ganymed will enable Astellas to further expand our oncology presence by adding a late-stage antibody asset with the potential to establish a new pillar following Xtandi [enzalutamide].โ€

The deal is set to close over the next few weeks.

Matt Fellows

Related Content

Astellas and Elpiscience enter collaboration for novel bispecific macrophage engager

Elpiscience Biopharma and Astellas Pharma have announced that they have entered into a research collaboration …

Chemotherapy

EMA accepts Astellasโ€™ MAA for Zolbetuximab

Astellas Pharma has announced that the European Medicines Agency (EMA) has accepted the companyโ€™s marketing …

shaking-hands-gb7ac17374_1920

Astellas and Cullgen enter into $1.9bn strategic collaboration to progress protein degraders

Japanese pharmaceutical company Astellas and US-based clinical-stage biopharmaceutical company Cullgen have announced that they have …

The Gateway to Local Adoption Series

Latest content